Aarti Pharmalabs Limited has informed the Exchange about Credit Rating

Rating UpgradedCredit & Debt View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹963.00

prior close

₹956.20

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.3%-0.9% vs market

Pharmaceuticals peers, median of 151sector+0.3%-1.0% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.3

15m

+0.2

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.3-0.9+0.3-1.0

Next day

-1.3-0.2-1.0-0.1-1.2

-1.3-0.4-0.9-0.3-1.0

-2.9-0.4-2.4-0.9-2.0

-1.7-0.7-1.0-1.0-0.7

-2.5-1.0-1.5-1.1-1.4

-4.2-4.0-0.2-2.4-1.8

15d

-13.1-5.7-7.4-5.3-7.8

-19.1-5.0-14.1-5.5-13.7

-4.7-1.8-2.9-4.9+0.3

-12.9-5.3-7.6-7.7-5.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 151Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Pharmalabs Limited has received a credit rating upgrade from CRISIL Ratings for its long-term bank loan facilities, effective July 17, 2025. The rating was upgraded from 'Crisil A+/Positive' to 'Crisil AA-/Stable', covering total bank loan facilities of Rs. 700 crore. The facilities include cash credit lines across six banks (Kotak Mahindra, SBI, Axis Bank, Citi Bank, Standard Chartered, IDBI Bank) at Rs. 75 crore each, a Rs. 100 crore long-term loan from Citi Bank, and proposed fund-based and long-term bank facilities aggregating Rs. 150 crore. The stable outlook suggests CRISIL expects the company's credit profile to remain consistent over the medium term.

Likely market impact

This upgrade signals improved creditworthiness and stronger financial health, which may lower the company's future borrowing costs and boost investor confidence. Positive for shareholders as it reflects better financial stability.